https://www.statnews.com/2025/01/17/glp-1-drugs-compounded-weight-loss-drug-websites-fall-short-new-analysis/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-9NkFEY6LEQaEAcSFjANGPbEWKiMl2B59NtuCLumx8OD6iNWrh80zPB9LkKj0G9SMFxV1hdwXGAcUC26EGNxoIhxuQnOQ&_hsmi=343359550&utm_content=343359550&utm_source=hs_email
It’s hard to blame patients for being confused. When they pay cash for compounded versions of obesity drugs, they may assume they’re getting the same thing as brand-name Ozempic or Wegovy, FDA-approved and all, for a fraction of the price. But a new JAMA Health Forum study reveals that among 79 websites marketing compounded GLP-1s or prescriptions for them, 37% stated or implied that the drugs were FDA-approved. That’s not so. Nearly half didn’t include information about the drugs’ adverse effects, warnings, and contraindications and 41% of sites included unsupported efficacy claims. STAT’s Katie Palmer has more on this gray area of regulation.
Online Advertising of Compounded Glucagon-Like Peptide-1 Receptor Agonists
https://jamanetwork.com/journals/jama-health-forum/fullarticle/2829225?utm_term=011725&utm_campaign=ftm_links&utm_medium=referral&_hsenc=p2ANqtz-9Md0RD_z3-0BFYIU_bDyeJgbxJbdCCo7dQNGCW2ChfOHtLwq3zgxBQ0AadZ7FsGhdzZa9BLWaghGwSipcOsQ8Y28GqhQ&_hsmi=343359550&utm_source=For_The_Media
No hay comentarios:
Publicar un comentario